HighIQCommunity.Com

3,912,376 words. 4,530 posts.

The War on Polio Just Entered Its Most Dangerous Phase

by | Dec 12, 2019 | News

Attitude is a little thing that makes a big difference.

— Winston Churchill

The War on Polio Just Entered Its Most Dangerous Phase

Though victory is close, the eradication campaign is on some very fragile ground.

  • Facebook
  • Twitter
  • Email
Photograph: Bettmann/Getty Images

This time two years ago, it must have felt as though the long international campaign to eradicate polio—launched in 1988 and decades past its hoped-for end date—was at last nearing its goal. There were only 17 cases of naturally occurring polio in the world in 2017, half the number from the year before and incomprehensibly fewer than the 350,000 cases that occurred annually when the campaign began.

The picture looks different now. The count for 2019 won’t be concluded until next year, but so far this year there have been 117 cases of naturally occurring polio. And in a galling development, there have been an additional 216 cases of what is called “vaccine-derived polio”—an accidental byproduct of the eradication campaign, brought into being by the campaign’s own vaccines.

In other words, there now exist more cases of polio paralysis caused by vaccines than there are cases caused by the original wild virus. It’s a stunning setback for the hard-fought program, overshadowing the news in October that its relentless rounds of vaccinations have eradicated two of the world’s three wild strains of virus. The campaign now finds itself mired in an asymptote of never quite getting there—a new phase in the fight that may be the most dangerous of all.

To step back for some history: Polio causes paralysis, of course (Franklin Delano Roosevelt, who concealed his wheelchair use while in the White House, might be its most famous historical victim), but it has been prevented by vaccination since 1955. By two vaccines, actually: an injected one that uses killed virus to evoke an immune response, and an oral vaccine that uses weakened live viruses. Both of these originally contained cocktails of all three polio strains.

The reason two vaccines exist stems from a long-ago scientific rivalry between Jonas Salk, who developed the first, injectable vaccine, and Albert Sabin, who produced the live-virus vaccine a few years later. But the reason both are still in use comes down to economics, as well as to calculations of probability.

The injectable vaccine confers durable immunity quickly: Children are 95 percent protected by their second shot at 4 months old, and completely protected by their third shot anywhere between 6 and 18 months. (A fourth booster shot comes before entering school.) But this version is more expensive to produce than Sabin’s, and its administration requires both a trained professional to give the shot and a system for safely collecting used needles afterward—factors that confine its use to industrialized countries with big health budgets and plenty of health workers.

The oral vaccine is relatively cheap to make and easy to give. Administration requires just dripping the liquid vaccine into a child’s mouth, which anyone who has received a brief coaching can manage it. That has made it the mainstay of the worldwide campaign, administered to millions of children by millions of members of Rotary International, which shares leadership of the campaign with the World Health Organization, the Centers for Disease Control and Prevention, and the Gates Foundation.

The oral vaccine also confers immunity in a less predictable manner. Under ideal conditions, four doses before a child is 4 months old will do the trick. Unfortunately, most of the places where polio has persisted longest don’t offer ideal conditions. When poverty or politics or civil unrest keep adequate doses from arriving, children who haven’t received a sufficient number remain vulnerable. So do any babies born into a community since the last time the vaccinators came around.

When that happens, polio bounces back. That is the situation in Pakistan and Afghanistan, the two countries where wild polio has never stopped circulating. They collectively have 117 cases this year; they had only 33 in all of 2018.

In Afghanistan, the problem has been religious unrest. The Taliban imposed overlapping bans on vaccination, both in big events and in house-to-house “mop-up” days afterward. (They are now allowing vaccine to be administered in public buildings, but not in homes.) In Pakistan, the issue is political change. The national election in July 2018 triggered turnover in personnel throughout the bureaucracy, which led to public health officials dropping and picking up tasks without smooth handoffs.

“We have lost basically a year and a half,” says Michel Zaffran, WHO’s director of polio eradication. “The number of children who are susceptible to contracting the disease is increasing very rapidly, and we could actually have explosive outbreaks.”

There’s a further complication. The eradication campaign didn’t choose the oral vaccine for worldwide distribution just for its cost and ease of use. The decision to use the live formula was also influenced by a quirk that made that version especially appealing as a public health tool: the fact that a dose given to one child could actually protect several children.

It works like this. Live poliovirus, both the original wild type and the weakened vaccine version, attaches and replicates in tissues that line the gut. That means anyone infected with polio can pass the virus along in feces. But it also means that a child who has received the weakened vaccine virus can pass the protective variety along instead, making them a secondary source of protection for other children who didn’t receive the drops.

The gain of passing along vaccine virus comes with a risk, though, and this is what has backfired on the polio campaign. Roughly once out of every 2.5 million doses given, the weakened vaccine virus reverts in the gut to the ferocity of wild-type polio, making a vaccinated child a potential source of infection instead of protection.

That probability was acceptable in the early days, when it seemed the campaign would be over quickly. Billions of doses later, the calculation looks different. And it’s been made more complicated still by a decision the eradication campaign made the first time one of the strains of polio virus was eradicated in the wild. In April 2016, those in charge switched from using a three-strain vaccine to a two-strain one. Officials at the time described the switch as a gamble worth taking. The strain that was dropped (called “type 2”) does a better job of attaching to the gut, so its presence in the vaccine could interfere with establishing immunity to the other two, still-circulating strains. With type 2 polio gone from the world, not inducing immunity to it in future cohorts of kids seemed a worthwhile risk.

SUBSCRIBE

Subscribe to WIRED and stay smart with more of your favorite Ideas writers.

In fact, vaccine-strain type 2 persisted in children who were not fully immune, and it rebounded. Most of the vaccine-derived outbreaks now occurring are caused by type 2. The eradication campaign has chased those outbreaks with a supplementary vaccine that contains only type 2, and is also pushing development of a new type 2 vaccine. But the persistence of type 2 outbreaks has brought home the fact that the campaign probably cannot risk refining the vaccine again, to only the type 1 strain of the virus—even though that is the strain that most needs curbing in the world.

Researchers within the campaign acknowledge that vaccine-derived polio is a real risk, but one worth taking overall. “The program has prevented 18 million children from being paralyzed by polio,” says John Vertefeuille, the CDC’s polio eradication branch chief. “To date we have seen less than 1,200 cases of vaccine-derived polio, against a backdrop of delivering billions of doses of vaccine.”

It’s also a risk that should go away someday. Plans call for the last phases of the campaign to roll out one round of the injected vaccine across the world. (It carries no risk of creating vaccine-derived strains because it uses killed viruses and bypasses the gut.) But because the injectable version is costly and limited in supply, it can only be used to seal the achievement, not to tamp down the epidemic’s repeated flare-ups.

Paradoxically, it is the success of the polio campaign that has exposed its fragility. The moment when the end comes into view and a final push is most needed, that turns out to also be the moment when governments find other uses for funding, and when communities grow tired of hauling their kids out for yet another round of drops. The campaign is 31 years old; it has consumed entire careers. It will have to find fresh energy, at a delicate moment, to make it to its goal.

More Great WIRED Stories

  • The strange life and mysterious death of a virtuoso coder
  • Teaching self-driving cars to watch for unpredictable humans
  • Wild juxtapositions of Saudi Arabia modern and ancient
  • A journey to Galaxy's Edge, the nerdiest place on earth
  • Burglars really do use Bluetooth scanners to find laptops and phones
  • 👁 Will AI as a field "hit the wall" soon? Plus, the latest news on artificial intelligence
  • ✨ Optimize your home life with our Gear team’s best picks, from robot vacuums to affordable mattresses to smart speakers.

Featured VideoSurgeon Breaks Down 22 Medical Scenes From Film & TV More from WIREDiconPlayVideoSurgeon Breaks Down 22 Medical Scenes From Film & TV

Annie Onishi, trauma surgery and critical care fellow, takes a look at more emergency room and operating room scenes from a variety of television shows and movies and breaks down how accurate they really are.

Wired

WIRED is where tomorrow is realized. It is the essential source of information and ideas that make sense of a world in constant transformation. The WIRED conversation illuminates how technology is changing every aspect of our lives—from culture to business, science to design. The breakthroughs and innovations that we uncover lead to new ways of thinking, new connections, and new industries.

  • Facebook
  • Twitter
  • Pinterest
  • Youtube
  • Instagram

More From WIRED

  • Subscribe
  • Newsletter
  • FAQ
  • Wired Staff
  • Press Center

Contact

  • Advertise
  • Contact Us
  • Customer Care
  • SecureDrop
  • Jobs
  • RSS
  • Site Map
  • Accessibility Help
  • Condé Nast Store

© 2019 Condé Nast. All rights reserved. Use of this site constitutes acceptance of our User Agreement (updated 1/1/20) and Privacy Policy and Cookie Statement (updated 1/1/20) and Your California Privacy Rights. Do Not Sell My Personal Information Wired may earn a portion of sales from products that are purchased through our site as part of our Affiliate Partnerships with retailers. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of Condé Nast. Ad Choices


View Original Article

Site VisitorsMap

Recent News

Site Statistics

105 registered users
3,912,376 words
4,530 posts, 2 comments
8579 images